# Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

> **NCT03081143** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 429 (actual)

## Conditions studied

- Advanced Gastric or EGJ Cancer

## Interventions

- **DRUG:** FOLFIRI
- **DRUG:** Ramucirumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03081143
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-10
- **Primary completion:** 2026-05
- **Final completion:** 2026-12
- **Target enrollment:** 429 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03081143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03081143, "Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03081143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*